Eye drops and preparation method thereof

A technology of eye drops and solutions, which is applied in the direction of pharmaceutical formulas, medical preparations containing active ingredients, peptide/protein components, etc., can solve the problem of lack of anti-corneal neovascularization and anti-inflammatory dual-effect eye drops, etc., to achieve Prevention and treatment of corneal neovascularization, reduction of complications and sequelae, prevention and treatment of corneal neovascularization

Inactive Publication Date: 2014-05-21
南昌大学第一附属医院 +1
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The purpose of the embodiments of the present invention is to provide an eye drop and its preparation method, aiming to solve the problem of lack of eye drop products with dual efficacy of anti-corneal neovascularization and anti-inflammation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eye drops and preparation method thereof
  • Eye drops and preparation method thereof
  • Eye drops and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0077] Such as figure 1 Shown, the preparation method of eye drop for the treatment of corneal disease of the present invention comprises the following steps:

[0078] S101: According to the formula of eye drops, including by volume percentage: bovine serum 0.1%-5%, thickener 5%-15%, acid-base adjustment solution 1%-5%, antibiotic 0.5%-2%, recombinant Nodinhibit -1 protein 5% ~ 20%, the rest is balanced salt solution, prepare materials;

[0079] S102: Add the thickener, bovine serum, antibiotics and recombinant Nodinhibit-1 protein to the balanced salt solution and mix evenly, adjust the pH value to 7.2-7.4 with an acid-base regulator, and adjust the osmotic pressure to 350mOsm / L~380mOsm / L, sterilized by membrane filtration to get Nodinhibit-1 eye drops;

[0080] Step S102 can also be to make the recombinant Nodinhibit-1 protein into sterile micropowder, dissolve bovine serum in balanced salt solution, adjust the pH value to 7.2-7.4 with an acid-base regulator, and steriliz...

Embodiment 1

[0084] Based on 10ml of eye drops, 7.4ml of PBS is used as the base solution, containing 200μl of fetal bovine serum, 100μl of low-molecular dextran, 200μl of HEPES, 100μl of tobramycin, 2ml of recombinant Nodinhibit-1 protein, the pH value is 7.2-7.4, and the osmotic pressure is 350~380mOsm / L.

[0085] Preparation method 1: Dissolve 100 μg of recombinant Nodinhibit-1 protein and 100 μg of low-molecular dextran in 2ml of PBS solution, then mix with 200 μl of fetal bovine serum, 200 μl of 1M HEPES and 100 μl of 10% tobramycin, add PBS solution to 10 ml, and adjust the pH The value is 7.2-7.4, the osmotic pressure is 350-380mOsm / L, and it is sterilized by filtration through a 0.2μm membrane to obtain Nodinhibit-1 eye drops.

[0086] Preparation method 2: Make 100 μg Nodinhibit-1 into sterile micropowder, mix 100 μg low-molecular dextran, 200 μl fetal bovine serum, 1M HEPES 200 μl, 10% tobramycin 100 μl and 9.4ml PBS, adjust the pH value to 7.2-7.4, pass through a 0.2 μm membrane...

Embodiment 2

[0088] Based on 10ml of eye drops, 7.4ml of HBSS as the base solution, containing 200μl of fetal bovine serum, 100μl of low-molecular dextran, 200μl of HEPES, 100μl of tobramycin, 2ml of recombinant Nodinhibit-1 protein, pH value of 7.2-7.4, osmotic pressure of 350~380mOsm / L.

[0089] Preparation method 1: Dissolve 100 μg of recombinant Nodinhibit-1 protein and 100 μg of low-molecular dextran in 2ml of HBSS solution, then mix well with 200 μl of fetal bovine serum, 200 μl of 1M HEPES and 100 μl of 10% tobramycin, add HBSS solution to 10 ml, and adjust the pH The value is 7.2-7.4, the osmotic pressure is 350-380mOsm / L, and it is sterilized by filtration through a 0.2μm membrane to obtain Nodinhibit-1 eye drops.

[0090] Preparation method 2: Make 100 μg Nodinhibit-1 into sterile micropowder, mix 100 μg low-molecular-weight dextran, 200 μl fetal bovine serum, 1M HEPES 200 μl, 10% tobramycin 100 μl and 9.4 ml HBSS, adjust the pH value to 7.2-7.4, pass through a 0.2 μm membrane S...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses eye drops and a preparation method thereof. The eye drops for treating keratonosus comprise the following components in percentage by volume: 0.1-5 percent of bovine serum, 5-15 percent of a thickening agent, 1-5 percent of a pH regulating agent, 0.5-2 percent of antibiotics, 5-20 percent of recombinant Nodinhibit-1 protein, and the balance of balanced salt solution. The preparation method of the eye drops for treating keratonosus comprises the following steps: uniformly mixing the thickening agent, the bovine serum, the antibiotics and the recombinant Nodinhibit-1 protein in the balanced salt solution, regulating the pH value to be 7.2-7.4 with the pH regulating agent, and regulating the osmotic pressure to be 350-380mOsm / L with an osmotic pressure buffering agent; and performing membrane filtration and sterilization to obtain the Nodinhibit-1 eye drops. The method is simple and reliable, and is easy to implement; the eye drops are simple in components, relatively low in cost and convenient to prepare. The eye drops do not contain hormone components, and can be used for a long time, so that occurrence of complications and sequelae in the administration period can be greatly reduced; bovine serum is added, so that adverse responses caused by using other serums can be remarkably reduced.

Description

technical field [0001] The invention belongs to the technical field of corneal disease treatment, in particular to an eye drop and a preparation method thereof. Background technique [0002] Corneal disease is one of the major blinding eye diseases in my country and the second leading cause of vision loss. Every year, 1.5 to 2 million new corneal blindness is caused by keratitis and corneal damage, which seriously threatens the health of patients. Among corneal diseases, infectious keratitis plays an important role. It is initially conservatively estimated that 500,000 people worldwide suffer from infectious keratitis every year. Because the cornea is located in the front, there is a greater chance of injury and infection. Therefore, when the cornea is attacked by trauma or pathogenic microorganisms, infectious inflammation is very likely to occur. Under normal physiological conditions, the cornea is transparent and has no blood vessels, and the limbal blood supply is rich,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61P27/02A61K31/702A61K31/7036A61K35/16
Inventor 邵毅李程韩云裴重刚高桂平
Owner 南昌大学第一附属医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap